CY1123719T1 - Πρωτεϊνες συντηξης θραυσματων ανθρωπινων πρωτεϊνων για τη δημιουργια τακτικα πολυμερισμενων συνθεσεων fc ανοσοσφαιρινων με ενισχυμενη δεσμευση συμπληρωματος - Google Patents

Πρωτεϊνες συντηξης θραυσματων ανθρωπινων πρωτεϊνων για τη δημιουργια τακτικα πολυμερισμενων συνθεσεων fc ανοσοσφαιρινων με ενισχυμενη δεσμευση συμπληρωματος

Info

Publication number
CY1123719T1
CY1123719T1 CY20211100019T CY211100019T CY1123719T1 CY 1123719 T1 CY1123719 T1 CY 1123719T1 CY 20211100019 T CY20211100019 T CY 20211100019T CY 211100019 T CY211100019 T CY 211100019T CY 1123719 T1 CY1123719 T1 CY 1123719T1
Authority
CY
Cyprus
Prior art keywords
fusion proteins
immunospherein
constitutes
generation
human protein
Prior art date
Application number
CY20211100019T
Other languages
English (en)
Inventor
David S. Block
Henrik Olsen
Original Assignee
Gliknik Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57885189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1123719(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gliknik Inc. filed Critical Gliknik Inc.
Publication of CY1123719T1 publication Critical patent/CY1123719T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)

Abstract

Η παρούσα εφεύρεση περιλαμβάνει μια σειρά πλήρως ανασυνδυασμένων πολυμερισμένων μορφών Fc ανοσοσφαιρίνης οι οποίες παρουσιάζουν με αυτόν τον τρόπο πολυσθενείς Fc ανοσοσφαιρίνες σε υποδοχείς ανοσοκυττάρων. Οι πρωτεΐνες σύντηξης υφίστανται τόσο ως ομοδιμερή όσο και ως πολυμερή κλάσματα υψηλής τάξης, που ονομάζονται stradomers. Η εφεύρεση περιλαμβάνει stradomers που αυξάνουν τον πολυμερισμό και δεσμεύονται προτιμησιακά στο συμπλήρωμα και που είναι χρήσιμα στη θεραπεία και πρόληψη ασθενειών.
CY20211100019T 2015-07-24 2021-01-13 Πρωτεϊνες συντηξης θραυσματων ανθρωπινων πρωτεϊνων για τη δημιουργια τακτικα πολυμερισμενων συνθεσεων fc ανοσοσφαιρινων με ενισχυμενη δεσμευση συμπληρωματος CY1123719T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562196478P 2015-07-24 2015-07-24
PCT/US2016/043746 WO2017019565A2 (en) 2015-07-24 2016-07-22 Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced complement binding

Publications (1)

Publication Number Publication Date
CY1123719T1 true CY1123719T1 (el) 2022-05-27

Family

ID=57885189

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100019T CY1123719T1 (el) 2015-07-24 2021-01-13 Πρωτεϊνες συντηξης θραυσματων ανθρωπινων πρωτεϊνων για τη δημιουργια τακτικα πολυμερισμενων συνθεσεων fc ανοσοσφαιρινων με ενισχυμενη δεσμευση συμπληρωματος

Country Status (23)

Country Link
US (1) US20180244772A1 (el)
EP (2) EP3325011B3 (el)
JP (2) JP6937737B2 (el)
KR (2) KR102649702B1 (el)
CN (2) CN116063510A (el)
AU (2) AU2016297862C1 (el)
BR (1) BR112017028550A2 (el)
CA (1) CA2991254A1 (el)
CY (1) CY1123719T1 (el)
DK (1) DK3325011T6 (el)
ES (1) ES2846024T7 (el)
FI (1) FI3325011T6 (el)
HK (1) HK1254447A1 (el)
HU (1) HUE053062T2 (el)
IL (2) IL256879B2 (el)
LT (1) LT3325011T (el)
MX (2) MX2018000587A (el)
PL (1) PL3325011T6 (el)
PT (1) PT3325011T (el)
RU (2) RU2737378C2 (el)
SI (1) SI3325011T1 (el)
TW (2) TWI729993B (el)
WO (1) WO2017019565A2 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214321A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
CA3029744A1 (en) 2016-07-22 2018-01-25 Gliknik Inc. Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding
JP2020500856A (ja) 2016-12-09 2020-01-16 グリックニック インコーポレイテッド 多価ｆｃ化合物を用いる炎症性疾患の治療方法
TW201835098A (zh) * 2016-12-09 2018-10-01 美商吉林尼克公司 製備最佳化之多聚化斯塔都聚體(stradomer) gl-2045
CA3085385A1 (en) 2017-12-14 2019-06-20 CSL Behring Lengnau AG Recombinant igg fc multimers for the treatment of neuromyelitis optica
AU2020344164A1 (en) 2019-09-13 2022-04-14 CSL Behring Lengnau AG Recombinant IgG Fc multimers for the treatment of immune complex-mediated kidney disorders
CN115298544A (zh) * 2020-03-26 2022-11-04 电化株式会社 含有Fc区域的一部分缺失的抗体的试剂
CN114478741B (zh) * 2021-12-31 2023-03-07 苏州大学 contactin 6蛋白突变体及其编码基因、表达载体与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) * 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
ES2109362T3 (es) 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US20150071948A1 (en) * 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
WO2008114011A2 (en) * 2007-03-19 2008-09-25 Medimmune Limited Fc polypeptide variants obtained by ribosome display methodology
CA2688490C (en) * 2007-06-01 2022-06-21 Scott E. Strome Immunoglobulin constant region fc receptor binding agents
US8362210B2 (en) * 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
CN105820256A (zh) * 2010-07-28 2016-08-03 格利克尼克股份有限公司 天然人蛋白片段的融合蛋白以产生有序多聚化免疫球蛋白fc组合物
EP2635607B1 (en) * 2010-11-05 2019-09-04 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
DK2654780T3 (en) * 2010-12-23 2017-04-10 Janssen Biotech Inc ACTIVE PROTEASE-RESISTANT ANTIBODY-FC MUTANTS
US20140170159A9 (en) * 2012-03-08 2014-06-19 Ge Wei Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
US9683044B2 (en) * 2012-08-20 2017-06-20 Gliknik Inc. Molecules with antigen binding and polyvalent FC gamma receptor binding activity
ES2773107T3 (es) * 2012-10-05 2020-07-09 Kyowa Kirin Co Ltd Composición de proteína heterodimérica
SG11201606597QA (en) 2014-03-05 2016-09-29 Ucb Biopharma Sprl Multimeric fc proteins

Also Published As

Publication number Publication date
KR102649702B1 (ko) 2024-03-21
TW201713697A (zh) 2017-04-16
JP6937737B2 (ja) 2021-09-22
HUE053062T2 (hu) 2021-06-28
EP3325011B1 (en) 2020-11-18
CN116063510A (zh) 2023-05-05
SI3325011T1 (sl) 2021-02-26
US20180244772A1 (en) 2018-08-30
PL3325011T3 (pl) 2021-05-17
PT3325011T (pt) 2021-01-27
TW202134433A (zh) 2021-09-16
AU2016297862C1 (en) 2022-12-15
KR20240042137A (ko) 2024-04-01
EP3325011A2 (en) 2018-05-30
TWI812951B (zh) 2023-08-21
ES2846024T3 (es) 2021-07-28
AU2016297862A1 (en) 2018-02-01
IL309260A (en) 2024-02-01
LT3325011T (lt) 2021-01-25
IL256879B2 (en) 2024-05-01
RU2737378C2 (ru) 2020-11-27
JP7122440B2 (ja) 2022-08-19
ES2846024T7 (es) 2023-06-22
MX2022008337A (es) 2022-08-04
BR112017028550A2 (pt) 2018-09-04
CN107847599A (zh) 2018-03-27
DK3325011T3 (da) 2020-12-14
EP3325011A4 (en) 2019-03-13
DK3325011T6 (da) 2023-05-15
JP2018528167A (ja) 2018-09-27
KR20180031676A (ko) 2018-03-28
RU2018106332A (ru) 2019-08-26
AU2016297862B2 (en) 2022-06-09
PL3325011T6 (pl) 2023-06-26
JP2021167325A (ja) 2021-10-21
WO2017019565A3 (en) 2017-03-09
FI3325011T6 (fi) 2023-05-11
CA2991254A1 (en) 2017-02-02
AU2022224791A1 (en) 2022-10-06
RU2020138007A (ru) 2020-12-17
WO2017019565A2 (en) 2017-02-02
TWI729993B (zh) 2021-06-11
MX2018000587A (es) 2018-05-02
IL256879A (en) 2018-03-29
IL256879B1 (en) 2024-01-01
CN107847599B (zh) 2022-10-04
EP3828204A1 (en) 2021-06-02
HK1254447A1 (zh) 2019-07-19
EP3325011B3 (en) 2023-03-15
RU2018106332A3 (el) 2019-11-13

Similar Documents

Publication Publication Date Title
CY1123719T1 (el) Πρωτεϊνες συντηξης θραυσματων ανθρωπινων πρωτεϊνων για τη δημιουργια τακτικα πολυμερισμενων συνθεσεων fc ανοσοσφαιρινων με ενισχυμενη δεσμευση συμπληρωματος
CY1124252T1 (el) Anti-lag3 αντισωματα και θραυσματα συνδεσης αντιγονου
CY1124896T1 (el) Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων
CY1123215T1 (el) Πολυνουκλεοτιδια τα οποια κωδικοποιουν αντισωματα τρωκτικων με ανθρωπινους ιδιοτυπους και ζωα τα οποια διαθετουν αυτα
CY1122389T1 (el) Αντισωματα εναντι διεγειρομενου με γλυκοκορτικοειδες υποδοχεα παραγοντα νεκρωσης ογκου (gitr) και χρησεις αυτων
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
CY1124691T1 (el) Διειδικα αντισωματα ειδικα για pd1 και τιμ3
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
CY1124747T1 (el) Ανθρωπινα αντισωματα σε pd-1
CY1125102T1 (el) Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης
CY1121962T1 (el) Υποδοχεις τ κυτταρου
CY1121893T1 (el) Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων
CY1124979T1 (el) Κατασκευασματα πρωτεϊνης uspa2 και χρησεις αυτων
CY1120281T1 (el) Πρωτεϊνες μονης αλυσιδας αγωνιστες των υποδοχεων της trail
PH12017502129A1 (en) Antibodies against ox40 and uses thereof
PE20150023A1 (es) Proteinas de union a antigeno st2
PE20240111A1 (es) Moleculas de union a pd-1 y metodos de uso de las mismas
EA201791057A1 (ru) Антигенсвязывающие молекулы, содержащие тримерный лиганд семейства tnf
EP4321171A3 (en) Sirp alpha-antibody fusion proteins
EA201792184A1 (ru) Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3)
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
EA201692039A1 (ru) ИММУНОГЛОБУЛИНЫ, СВЯЗЫВАЮЩИЕ ЧЕЛОВЕЧЕСКИЕ Vγ9Vδ2 Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ
BR112016023948A2 (pt) proteínas fc multiméricas
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
BR112016022841A2 (pt) cadeia j modificada